PRMT1 expression predicts response to neoadjuvant chemotherapy for locally advanced uterine cervical cancer.
neoadjuvant chemotherapy
predictive marker
protein arginine methyltransferase 1
uterine cervical cancer
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
08
09
2020
accepted:
02
11
2020
entrez:
8
2
2021
pubmed:
9
2
2021
medline:
9
2
2021
Statut:
ppublish
Résumé
The standard care for patients with locally advanced cervical cancer is concurrent chemoradiotherapy. Successful neoadjuvant chemotherapy (NAC) can reduce tumor size and enable patients to be eligible for a hysterectomy, which can improve their prognosis. Selecting the right candidate for NAC is important since NAC failure results in switching to radiation therapy and can lead to a worse prognosis due to a delay in the initiation of the core therapy. Therefore, the identification of biomarkers that can predict the effect of NAC is essential. Previous reports have suggested a relationship between protein arginine methyltransferase (PRMT1) and chemoresistance in several types of cancer. PRMT1 has been demonstrated to methylate apoptosis signal-regulated kinase 1 and to inhibit its activity, thereby contributing to chemoresistance. The present study investigated the association between PRMT1 expression and the efficacy of NAC in locally advanced cervical cancer. Data from 53 patients with locally advanced uterine cervical cancer who were classified into two groups based on effective (n=28) and ineffective (n=25) responses to NAC treatment were evaluated. PRMT1 expression was investigated by immunohistochemistry and scored using a weighted scoring system. Additionally, the present study investigated the effect of RNA interference-mediated downregulation of PRMT1 on the sensitivity of cervical cancer cells to cisplatin
Identifiants
pubmed: 33552268
doi: 10.3892/ol.2020.12411
pii: OL-0-0-12411
pmc: PMC7798043
doi:
Types de publication
Journal Article
Langues
eng
Pagination
150Informations de copyright
Copyright: © Shimomura et al.
Références
World J Biol Chem. 2014 May 26;5(2):115-29
pubmed: 24921003
Int J Mol Med. 2005 Jan;15(1):41-7
pubmed: 15583826
Oncol Rep. 2000 Jan-Feb;7(1):141-4
pubmed: 10601608
Cell Death Dis. 2019 May 1;10(5):359
pubmed: 31043582
J Clin Oncol. 1995 Feb;13(2):444-51
pubmed: 7844607
Cell Rep. 2017 Nov 28;21(9):2447-2457
pubmed: 29186683
Ann Surg Oncol. 2007 Sep;14(9):2643-8
pubmed: 17562114
Oncotarget. 2014 Mar 15;5(5):1304-14
pubmed: 24675421
Int J Mol Med. 2004 Jul;14(1):101-5
pubmed: 15202023
Mol Cell. 2005 Apr 29;18(3):263-72
pubmed: 15866169
Cancer Res. 1995 Jan 15;55(2):237-41
pubmed: 7812951
N Engl J Med. 1999 Apr 15;340(15):1137-43
pubmed: 10202164
J Clin Oncol. 1991 Jun;9(6):970-7
pubmed: 1709686
Int J Gynaecol Obstet. 2009 May;105(2):103-4
pubmed: 19367689
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Oncol Rep. 2000 Jul-Aug;7(4):827-30
pubmed: 10854552
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cell Death Differ. 2012 May;19(5):859-70
pubmed: 22095282
Oncogene. 2003 Oct 20;22(47):7265-79
pubmed: 14576837
Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1337-45
pubmed: 7635773
Int J Oncol. 2001 Jun;18(6):1151-5
pubmed: 11351244
J Clin Invest. 2015 Dec;125(12):4529-43
pubmed: 26571401
J Clin Oncol. 2004 Mar 1;22(5):872-80
pubmed: 14990643